Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
35278027
DOI
10.1111/dth.15438
Knihovny.cz E-zdroje
- Klíčová slova
- alopecia areata, alopecia totalis, alopecia universalis, bimatoprost, eyelashes,
- MeSH
- alopecia areata * MeSH
- alopecie diagnóza farmakoterapie MeSH
- bimatoprost škodlivé účinky MeSH
- lidé MeSH
- oční řasy * MeSH
- prospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- bimatoprost MeSH
Bimatoprost is a synthetic prostaglandin structural analogue used among other indications to increase eyelash growth. The aim of this prospective, open-label study was to evaluate the safety and efficacy of topical bimatoprost in the treatment of eyelash loss in alopecia areata totalis (AT) and universalis (AU). Study subjects applied ophthalmic bimatoprost (0.3 mg/ml) solution to the eyelid margins once nightly for at least 12 weeks (mean treatment period was 30.6 weeks). A total of 16 out of 17 subjects completed the study. Only the subjects with eyelashes present at baseline experienced an increase in eyelash length and thickness. No new eyelash regrowth was induced. In patients with AT and AU topical bimatoprost affected existing eyelashes, but failed to induce regrowth of new eyelashes.
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Department of Dermatology University of Minnesota Minneapolis Minnesota USA
Department of Ophthalmology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Zobrazit více v PubMed
Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62:177-188.
Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366:1515-1525.
Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol. 2000;118:718-719.
Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol JEADV. 2010;24:481-485.
Roseborough I, Lee H, Chwalek J, et al. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol. 2009;60:705-706.
Ochoa BE, Sah D, Wang G, et al. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol. 2009;61:530-532.
Tosti A, Pazzaglia M, Voudouris S, Tosti G. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol. 2004;51:149-150.
Ross EK, Bolduc C, Lui H, Shapiro J. Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata. J Am Acad Dermatol. 2005;53:1095-1096.
Faghihi G, Andalib F, Asilian A. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. Eur J Dermatol. 2009;19:586-587.
Vila TO, Camacho Martinez FM. Bimatoprost in the treatment of eyelash universalis alopecia areata. Int J Trichol. 2010;2(2):86-88.
Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47(1):105-115.
Zaleski-Larsen LA, Ruth NH, Fabi SG. Retrospective evaluation of topical Bimatoprost and iris pigmentation change. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2017;43:1431-1433.
Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26:515-522.
